$KRTL Biotech Showcases Gastrointestinal Health Po
Post# of 99604
(Total Views: 41)
Posted On: 10/21/2025 11:31:49 AM
$KRTL Biotech Showcases Gastrointestinal Health Portfolio to Address Global Demand for Accessible Digestive Care
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=496738
KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company"
today announced that its majority-owned subsidiary, KRTL Biotech, Inc., is highlighting its international Gastrointestinal (GI) Care product line, which includes a range of formulations addressing digestive discomfort, acid-related disorders, and hydration needs across diverse patient populations.
The product line—developed and manufactured in collaboration with Industria Químico-Farmacéutica SIGMA Corp.—includes antacids, proton pump inhibitors, antidiarrheals, antiemetics, and oral rehydration therapies, all designed to meet the clinical and practical needs of pharmacies, public health systems, and hospital networks.
"Digestive care is a daily necessity for patients and providers alike," said Daniel Bishop, CEO of KRTL Biotech. "Our GI portfolio addresses everything from minor discomfort to acute dehydration, and these products are positioned for regional and global impact."
Key formulations include:
Omeprazole and Pantoprazole (acid reflux and GERD)
Aluminum hydroxide + magnesium combinations (antacid suspensions)
Loperamide and Racecadotril (antidiarrheals)
Simethicone and dimethicone (gas and bloating relief)
Electrolyte powders and oral hydration salts (rehydration)
Domperidone and metoclopramide (motility and nausea)
These products are manufactured under GMP-certified standards in Bolivia and are widely used across Latin America through both private and public channels. Several of these medications are included in national essential medicines lists and serve critical functions in pediatric, adult, and geriatric care.
"From pharmacies to emergency rooms, gastrointestinal therapies are essential in every healthcare environment," said Patricia Wilstermann, CEO of SIGMA. "We’ve built this line with both clinical consistency and broad accessibility in mind."
KRTL Biotech is currently reviewing potential U.S. and international regulatory designations for select GI products, including OTC Monograph eligibility and ANDA filings for prescription formulations. Certain hydration and antacid products may be prioritized for near-term export consideration due to their alignment with OTC use cases.
"Gastrointestinal health is a top-three pharmaceutical category globally," said Cesar Herrera, CEO of KRTL Holding Group Inc. "With SIGMA’s production expertise and KRTL Biotech’s international strategy, we are well-positioned to bring trusted digestive care products to new markets."
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=496738
KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company"
today announced that its majority-owned subsidiary, KRTL Biotech, Inc., is highlighting its international Gastrointestinal (GI) Care product line, which includes a range of formulations addressing digestive discomfort, acid-related disorders, and hydration needs across diverse patient populations. The product line—developed and manufactured in collaboration with Industria Químico-Farmacéutica SIGMA Corp.—includes antacids, proton pump inhibitors, antidiarrheals, antiemetics, and oral rehydration therapies, all designed to meet the clinical and practical needs of pharmacies, public health systems, and hospital networks.
"Digestive care is a daily necessity for patients and providers alike," said Daniel Bishop, CEO of KRTL Biotech. "Our GI portfolio addresses everything from minor discomfort to acute dehydration, and these products are positioned for regional and global impact."
Key formulations include:
Omeprazole and Pantoprazole (acid reflux and GERD)
Aluminum hydroxide + magnesium combinations (antacid suspensions)
Loperamide and Racecadotril (antidiarrheals)
Simethicone and dimethicone (gas and bloating relief)
Electrolyte powders and oral hydration salts (rehydration)
Domperidone and metoclopramide (motility and nausea)
These products are manufactured under GMP-certified standards in Bolivia and are widely used across Latin America through both private and public channels. Several of these medications are included in national essential medicines lists and serve critical functions in pediatric, adult, and geriatric care.
"From pharmacies to emergency rooms, gastrointestinal therapies are essential in every healthcare environment," said Patricia Wilstermann, CEO of SIGMA. "We’ve built this line with both clinical consistency and broad accessibility in mind."
KRTL Biotech is currently reviewing potential U.S. and international regulatory designations for select GI products, including OTC Monograph eligibility and ANDA filings for prescription formulations. Certain hydration and antacid products may be prioritized for near-term export consideration due to their alignment with OTC use cases.
"Gastrointestinal health is a top-three pharmaceutical category globally," said Cesar Herrera, CEO of KRTL Holding Group Inc. "With SIGMA’s production expertise and KRTL Biotech’s international strategy, we are well-positioned to bring trusted digestive care products to new markets."
(0)
(0)